SHARx Names Veteran Clinician Dr. Tom Grissom, MD, First Medical Director

0
161

ST. LOUIS– SHARx, one of the nation’s fastest-growing patient advocacy companies, announced today that they have hired Dr. Tom Grissom, a 26-year clinical veteran as the company’s first Medical Director. Dr. Grissom joins SHARx from the Algone Pain Intervention Clinic in Wasilla, AK, where he was a founder and CEO. He will provide support to the SHARx clinical team, including its staff pharmacist.

“I am delighted to welcome Dr. Grissom to SHARx, where his clinical expertise and experience make him an asset to our most vulnerable members,” said SHARx CEO Corey Durbin. “Patient advocacy is a calling for which Dr. Grissom has a passion that goes back decades, and by bringing that passion to SHARx, he will help us better serve our members,” he continued.

Dr. Grissom is a graduate of the University of Washington Medical School. He did his residency at the University of Missouri, Columbia, followed by a Fellowship in pain management at Syracuse University in NY. He has an extensive array of career accomplishments, including serving as a practitioner, medical director, as well as founder and CEO of the largest pain management clinic in the state of Alaska.

“One of the biggest challenges facing the American healthcare system is ensuring that patients have affordable access to the lifesaving and life-altering medications they need,” said Dr. Grissom. “SHARx plays a critical role in that process, and I am proud to join their team. The chance to positively impact the lives of those in need is incredibly exciting.”

SHARx is a patient advocacy company that helps the underinsured get affordable access to lifesaving and life-altering medications, some of which can cost $1.5 million annually. In a country where the top 17 drugs generate more revenue for the big pharma companies that own the patents than in the rest of the world combined, many patients and families are unable to secure needed medications simply because they cost too much.

“Access to medication should not be for the elect few,” said Dr. Grissom, “but for everyone who has a need. We’ve got to do better at getting access for all, and SHARx will allow me to make a larger impact than the one patient at a time approach I use as a doctor. The huge potential impact has me more excited to be in the healthcare space than I have been in some time,” he added.